Compare TG Therapeutics Inc (TGTX) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while YieldMax TSLA Option Income Strategy ETF trades at $21.47. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| TGTX | TSLY | |
|---|---|---|
Market Cap | $7.64B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $59.06 | $48.25 |
52-Week Low | $26.94 | $20.49 |
Enterprise Value | $7.84B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
TSLY trades at $21.62, down 0.51% today, with a bearish technical outlook per moving averages and mixed oscillators. The ETF maintains high dividend distributions, with recent payouts ranging from $0.21 to $0.52 weekly, but faces capped upside risk due to its option income strategy structure. Recent news highlights concerns over missed Tesla rallies and volatility shifts, impacting sentiment.
Outlook is cautious due to structural limitations in capturing Tesla's gains, with risks including volatility dependency and competitive ETF strategies. The high yield attracts income seekers, but total return potential may be constrained if Tesla appreciates significantly, warranting careful risk assessment for equity-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
